Amazon $AMZN is launching a GLP-1 management program through its primary care arm, One Medical, that integrates obesity treatment into routine care and pairs it with fulfillment through Amazon Pharmacy.
According to CNBC, the program combines in-person and virtual appointments, medication management, and pharmacy services in one place. Amazon describes obesity as a long-term condition that needs ongoing care, not just a one-time prescription.
For patients with insurance, prices start at $25 per month. Those paying cash can get oral GLP-1 medications starting at $149 per month. Injectable treatments, such as Novo Nordisk's Wegovy and Eli Lilly $LLY's Zepbound, start at $299 per month without insurance, according to the company.
Customers already using GLP-1 treatments can renew their prescriptions at any time. Messaging consultations cost $29, and video visits are $49. Amazon's same-day delivery service now covers about 3,000 cities and is expected to reach 4,500 cities by 2027.
"By expanding access to the latest GLP-1 medications with upfront, clear pricing, we're making it easier for customers to get the treatments their health care providers prescribe and to stay on those medications because they are delivered reliably directly to patients," said Tanvi Patel, VP and GM of Amazon Pharmacy, in a statement.
News of the launch sent shares of Hims & Hers Health, Viking Therapeutics, Amgen $AMGN, and Septerna — each with exposure to the obesity drug market — declining on Tuesday.